Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1963-1968

  Laessig, Dorit ^a   Nagel, Dorothea ^a   Heinemann, Volker ^a   Untch, Michael ^b   Kahlert, Steffen ^a   Bauerfeind, Ingo ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HELIOS Klinikum   (Germany)

Author keywords

CA 15 3; CEA; Metastatic breast cancer; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATIONAL STUDY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34250708359     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Lamerz R, Stieber P and Fateh-Moghadam A: Serum marker combinations in human breast cancer (review). In Vivo 7: 607-613, 1993.
3. Vizcarra E, Lluch A, Cibrian R, Jarque F, Alberola V, Belloch V and Garcia-Conde J: Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 37: 209-216, 1996.
4. Stieber P, Sauer H and Untch M: Tumor markers in breast cancer. J Lab Med 25: 343-352, 2001.
5. Oncology, A. S. o. C. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996. J Clin Oncol 14: 2843-2877, 1996.
6. Jaeger W, Eibner K, Loffler B, Gleixner S and Kramer S: Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. Anticancer Res 20: 5179-5182, 2000.
7. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M et al: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36: 41-48, 1995.
8. Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L: Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64: 154-158, 1991.
9. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Soletormos G and Stieber P: Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 26: 281-293, 2005.
10. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu noz M, Farrus B, Latre ML, Escriche C, Estape J and Ballesta AM: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 51: 109-119, 1998.
11. van Dalen A: Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res 16: 2345-2349, 1996.
12. Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A and Bruscagnin G: The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer 63: 809-813, 1991.
13. Robertson JF, Pearson D, Price MR, Selby C, Pearson J, Blamey RW and Howell A: Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 33: 403-410, 1991.
14. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury JR, Gronberg H, Kumpulainen E and Blamey RW: The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer 35: 47-53, 1999.
15. Robertson JF, Whynes DK, Dixon A and Blamey RW: Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 72: 174-177, 1995.
16. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G and Dogliotti L: Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A: 2082-2084, 1994.
17. Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ and Duffy MJ: CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70: 2831-2834, 1992.
18. Al-Jarallah MA, Behbehani AE, el-Nass SA, Temim L, Ebraheem AK, Ali MA and Szymendera JJ: Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 19: 74-79, 1993.
19. Safi F, Kohler I, Rottinger E and Beger H: The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 68: 574-582, 1991.
20. Colomer R, Ruibal A and Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-1681, 1989.
21. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL and Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773-782, 1987.
22. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J and Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724-733, 2000.
23. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C and Piccart MJ: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20: 3114-3121, 2002.
24. Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P and Piccart MJ: Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39: 2439-2449, 2003.
25. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R and Salvador L: Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 13: 123-133, 1989.